Dr. Stanley Hirsch
Dr. Stanley Hirsch is the Group CEO of FuturaGene Ltd. Prior to joining FuturaGene, Dr. Hirsch served as general manager of two diagnostics development companies and a drug development company. Dr. Hirsch served as a Chairman of a NASDAQ-traded specialty pharmaceutical company from 2017 to 2020 and as Board Director for a research products company inter alia, and has advised various venture capital funds. He currently serves on the Board of Barcode Nanotech. He received his D. Phil. from Oxford University in Cell Biology and Immunology and his B.SC and B.Sc. (Med) Honours from the University of Cape Town.